Goldman Sachs
SLN

Goldman Sachs’s Silence Therapeutics SLN Stock Holding History

Goldman Sachs’s Portfolio SLN Stock Details SLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$277K Buy
52,511
+34,397
+190% +$189K ﹤0.01% 5935
2025
Q4 		$110K Sell
18,114
-4,530
-20% -$29K ﹤0.01% 6175
2025
Q3 		$118K Buy
+22,644
New +$126K ﹤0.01% 6058
2025
Q2 		– Sell
-24,375
Closed -$68.7K – 6389
2025
Q1 		$68.7K Sell
24,375
-12,510
-34% -$61.1K ﹤0.01% 5843
2024
Q4 		$254K Buy
36,885
+6,253
+20% +$80.7K ﹤0.01% 5554
2024
Q3 		$557K Buy
30,632
+14,376
+88% +$267K ﹤0.01% 4988
2024
Q2 		$309K Sell
16,256
-5,483
-25% -$117K ﹤0.01% 5090
2024
Q1 		$470K Buy
+21,739
New +$473K ﹤0.01% 4775
2023
Q4 		– Sell
-266,667
Closed -$2.62M – 5820
2023
Q3 		$2.62M Sell
266,667
-143,333
-35% -$1.06M ﹤0.01% 3548
2023
Q2 		$2.25M Sell
410,000
-250,000
-38% -$1.51M ﹤0.01% 3788
2023
Q1 		$4.09M Sell
660,000
-189
-0% -$2.23K ﹤0.01% 3229
2022
Q4 		$10.1M Buy
660,189
+189
+0% +$2.48K ﹤0.01% 2583
2022
Q3 		$6.62M Hold
660,000
– – ﹤0.01% 2889
2022
Q2 		$7.82M Sell
660,000
-305,815
-32% -$3.72M ﹤0.01% 2733
2022
Q1 		$18.4M Buy
965,815
+205,815
+27% +$4.1M ﹤0.01% 2121
2021
Q4 		$18.2M Buy
+760,000
New +$17.6M ﹤0.01% 2201

Other funds holding SLN

TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $515M AUM 24.47% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return

Goldman Sachs's SLN Position: Q1 2026 in Review

Goldman Sachs increased its Silence Therapeutics (SLN) stake by 190% in Q1 2026, buying an estimated $189K and bringing the position to 52,511 shares worth $277K. The position accounts for ﹤0.01% of the portfolio, ranked #5935.

Goldman Sachs first reported a position in SLN in Q4 2021 and has held it in 16 quarters since. The position peaked at $18.4M in Q1 2022. 56 funds tracked by Wall St. Rank hold SLN as of Q1 2026.

  • Goldman Sachs held 52,511 shares of Silence Therapeutics worth $277K as of Q1 2026.
  • Goldman Sachs bought 34,397 Silence Therapeutics shares in Q1 2026, an estimated $189K.
  • Silence Therapeutics made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #5935 holding.
  • Goldman Sachs first reported a position in Silence Therapeutics in Q4 2021 and has held it in 16 quarters since.
  • Goldman Sachs's Silence Therapeutics position peaked at $18.4M in Q1 2022.
  • 56 funds tracked by Wall St. Rank held Silence Therapeutics as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.